Skip to main content
Premium Trial:

Request an Annual Quote

IMIDomics, Gossamer Bio Form Immune-Mediated Inflammatory Disease Alliance

NEW YORK — IMIDomics said on Monday that it has partnered with drug developer Gossamer Bio on the discovery and development of new treatments for immune-mediated inflammatory diseases (IMID), beginning with inflammatory bowel disease.

IMIDomics has developed a platform that analyzes clinical and molecular data derived from an immune-mediated inflammatory disease biobank at Vall d’Hebron University Hospital in Spain to generate insights into disease biology.

Under the terms of the deal, Gossamer may select specific projects on which to collaborate with IMIDomics, beginning with IBD. Additional terms were not disclosed.

"IMIDomics … [has] assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking, and analytics," Gossamer CSO Luisa Salter-Cid said in a statement. "Their platform will drive a deeper understanding of IMID patients and disease biology, which we hope will inform our strategy for drug discovery and development."

In 2017, Barcelona, Spain-based IMIDomics began working with Celgene on the development of new immune-mediated inflammatory disease drugs.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.